Please select your view
Associate Professor Mirette Saad is a Consultant Chemical Pathologist and the National Director of Molecular Genetics at Australian Clinical Labs. She has a Fellowship with honours in Chemical and Molecular Pathology, with a Microbiology subspeciality, from Suez Canal University, Egypt. A/P Saad received her NHMRC-sponsored PhD degree in Cancer Genetics from Melbourne University and Peter MacCallum Cancer Institute.
Along with her teaching and research roles, A/P Saad is a registered medical practitioner with AHPRA, a Chemical Pathology Fellow (FRCPA) at the Royal College of Pathologists of Australasia, and a Member of the Australasian Association of Clinical Biochemists (MAACB). She is a Chair of the RCPA Chemical Pathology Advisory Committee, a Member of the RCPA Genetic Advisory Committee, AACB, and a Chair of the Precision Medicine Services at Australian Clinical Labs.
At Clinical Labs, A/Prof Mirette Saad leads the Molecular Genetic testing for non-invasive prenatal testing (NIPT), antenatal screening, personalised drug therapy, and cancer.
Associate Professor Chris Barnes is the National Director of Haematology and provides strategic direction nationally for haematology at Clinical Labs. He is a clinical and laboratory-trained haematologist who has been part of Melbourne Haematology and has worked with Clinical Labs (and previously Healthscope) for several years. A/Prof Barnes also works at the Royal Children’s Hospital and is the director of the Haemophilia Treatment Centre. He has experience in both management and leadership positions. A/Prof Barnes has active clinical research interests and is also director of Melbourne Haematology (Clinical) and Melbourne Paediatric Specialists.
Dr Hema Sitaraaman trained in Anatomical Pathology (Histopathology) in the United Kingdom. As part of her training, she has worked at the Royal Hallamshire Hospital (Sheffield), St. James’s University Hospital (Leeds), Calderdale Royal Hospital (Halifax), and Bradford Royal Infirmary (Bradford). She obtained her FRCPath in 2018 and completed her Master’s in Genomic Medicine in 2020 at the University of Manchester. After completing her senior registrar rotation, she began her consultant practice at the Royal Hallamshire Hospital in April 2020, specialising in Dermatopathology and Gynaecological Pathology.
In addition to histopathological reporting of primary and externally referred cases, Dr Sitaraaman was actively involved in teaching histopathology registrars and advanced biomedical practitioners. She conducted audit and service improvement projects, collaborated with biomedical scientists to validate new immunohistochemistry methods, streamlined the adoption of molecular practice in gynaecological cancer reporting, presented at central skin cancer and gynaecological cancer multidisciplinary team meetings, and provided formal educational supervision to trainees. She also held the roles of Gynaecological Cancer Molecular Lead and Trainee Teaching Coordinator, and was an active contributor to the South Yorkshire and Bassetlaw Gynaecological Cancer Clinical Delivery Group.
After working as a consultant for three years, Dr Sitaraaman migrated to Australia and joined the Australian Clinical Labs team at Bella Vista as an Anatomical Pathologist. Her primary areas of interest include Dermatopathology, Gynaecological Pathology, and Breast Pathology.
Dr Stanford graduated from the University of New South Wales in 2005. She completed Basic Physician Training, followed by Advanced Training in Chemical Pathology and Endocrinology. This included undertaking a year with a focus on bone disease at St Vincent’s hospital (Sydney), followed by a year of general clinical endocrine training at Prince of Wales Hospital. Dr Stanford then completed her joint training based at the Prince of Wales and Royal North Shore Hospital Laboratories. In 2019, she was awarded fellowship of both the Royal Australasian College of Physicians and The Royal College of Pathologists of Australasia. Dr Stanford then worked at Tan Tock Seng hospital laboratory in Singapore before returning to Australia to take up a Chemical Pathologist position at Australian Clinical Labs.
Effective from 1st November 2023, the MBS requirements for prostate-specific antigen (PSA) testing have changed.
This change is thanks to Rachael and Jonathan Casella, who advocated for carrier screening to be routine and free for all prospective parents.
Clinical Labs and Barwon Health Hospital Agree on Five Year Extension of Services
Latest updates regarding Australian Clinical Labs’ takeover offer for Healius Limited.